Filter Results
:
(3,383)
Show Results For
-
All HBS Web
(3,383)
- People (9)
- News (692)
- Research (2,156)
- Events (33)
- Multimedia (26)
- Faculty Publications (1,256)
Show Results For
-
All HBS Web
(3,383)
- People (9)
- News (692)
- Research (2,156)
- Events (33)
- Multimedia (26)
- Faculty Publications (1,256)
- June 2004 (Revised November 2004)
- Case
Acorda Therapeutics: Rebuilding the Spinal Cord
Acorda is an early-stage life science start-up with a promising product that is close to reaching the market (Phase III clinical trials). The company is grappling with how to expand its portfolio of molecules to make the business more sustainable. It faces classic...
View Details
Keywords:
Decision Making;
Science-Based Business;
Health Testing and Trials;
Business Startups;
Product Development;
Biotechnology Industry
Enriquez-Cabot, Juan, Jonathan West, Marina Kolesnik, and Fiona Murray. "Acorda Therapeutics: Rebuilding the Spinal Cord." Harvard Business School Case 604-014, June 2004. (Revised November 2004.)
- 16 Nov 2020
- News
Moderna Announces Promising Vaccine Trial Results
Moderna released promising news on the progress of their coronavirus vaccine this morning, noting that trials showed it to be 94.5% effective. “In this pandemic, what has been awful from a public health standpoint, an economic standpoint, is the worry people have to...
View Details
- 18 Feb 2016
- News
Challenge Aims to Speed Drug Trials Process
The HBS Health Care Initiative is seeking innovative ideas from the science, patient, business, and medical communities on how to transform trials for precision medicine. Through the HBS Precision Trials Challenge, it aims to bring diagnostics and therapies to market...
View Details
- 04 Sep 2019
- News
Advancing Diagnostics that Can Save Lives
Above: photo by Len Rubenstein No disease can be slowed or stopped until it is diagnosed. For diseases with available treatments, the facts are simple: The earlier they are detected, the higher the survival rates. Two companies at the Pagliuca Harvard Life Lab are...
View Details
Keywords:
Susan Young
- Profile
Mike Monagle
business and then moved into a strategic role managing company interests in Asia. As it became clearer that Mike wanted to build a business of his own, he recognized a need to expand his skills and “reflect on my future,” he says. “In the right program, I could View Details
- 2008
- Chapter
Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation
By: Arthur A. Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater...
View Details
Keywords:
Geographic Location;
Governing Rules, Regulations, and Reforms;
Health Testing and Trials;
Demand and Consumers;
Pharmaceutical Industry;
European Union;
Germany;
United States
Daemmrich, Arthur A. "Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation." Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, edited by Jean Paul Gaudillière and Volker Hess, 271–290. Berlin, Germany: Max-Planck-Institut für Wissenschaftsgeschichte, 2008.
- September 1991 (Revised August 1994)
- Background Note
Note on Pharmaceutical Industry Regulation
Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,...
View Details
Keywords:
Safety;
Industry Growth;
Marketing;
Research and Development;
Health Testing and Trials;
Economics;
Pharmaceutical Industry;
United States
Emmons, Willis M., III. "Note on Pharmaceutical Industry Regulation." Harvard Business School Background Note 792-002, September 1991. (Revised August 1994.)
- 2013
- Article
Planning Prompts as a Means of Increasing Preventive Screening Rates
By: Katherine L Milkman, John Beshears, James J. Choi, David Laibson and Brigitte C. Madrian
Keywords:
Reminder Systems;
Communication;
Economics;
Behavioral;
Primary Prevention;
Colonoscopy;
Memory;
Behavior;
Health Care and Treatment;
Health Testing and Trials;
Communication Strategy;
Health Industry
Milkman, Katherine L., John Beshears, James J. Choi, David Laibson, and Brigitte C. Madrian. "Planning Prompts as a Means of Increasing Preventive Screening Rates." Preventive Medicine 56, no. 1 (January 2013): 92–93.
- 15 Jan 2018
- News
A Better Business Model for Fighting Cancer
- 12 Aug 2019
- Working Paper Summaries
Case Histories of Significant Medical Advances
- Article
Use of Connected Digital Products in Clinical Research Following the COVID-19 Pandemic: A Comprehensive Analysis of Clinical Trials
By: Caroline Marra, William J. Gordon and Ariel Dora Stern
Objectives: In an effort to mitigate COVID-19 related challenges for clinical research, the U.S. Food and Drug Administration (FDA) issued new guidance for the conduct of ‘virtual’ clinical trials in late March 2020. This study documents trends in the use of...
View Details
Keywords:
Connected Digital Products;
Telehealth;
Remote Monitoring;
Health Testing and Trials;
Research;
Governing Rules, Regulations, and Reforms;
Information Technology
Marra, Caroline, William J. Gordon, and Ariel Dora Stern. "Use of Connected Digital Products in Clinical Research Following the COVID-19 Pandemic: A Comprehensive Analysis of Clinical Trials." BMJ Open 11, no. 6 (2021).
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire...
View Details
Keywords:
CV Ingenuity;
CVI;
Drug Eluting Balloon;
DEB;
Drug Eluting Stent;
Angioplasty Balloon;
FoxHollow;
Medical Device;
Medical Device Startup;
Premarket Approval;
PMA;
Lutonix;
Stellarex;
LEVANT;
ILLUMENATE;
Clinical Trials;
Peripheral Arterial Disease;
PAD;
Healthcare Startups;
Covidien;
Health Care and Treatment;
Health Testing and Trials;
Business Startups;
Commercialization;
Health Industry;
Medical Devices and Supplies Industry;
United States;
Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies." Harvard Business School Case 315-045, March 2015. (Revised January 2024.)
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords:
Health Testing and Trials;
Governing Rules, Regulations, and Reforms;
Valuation;
Product Development;
Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Testing and Trials;
Health Care and Treatment;
Business Model;
Problems and Challenges;
Pharmaceutical Industry;
Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The...
View Details
Keywords:
CV Ingenuity;
CVI;
Drug Eluting Balloon;
DEB;
Drug Eluting Stent;
Angioplasty Balloon;
FoxHollow;
Medical Device;
Medical Device Startup;
Premarket Approval;
PMA;
Lutonix;
Stellarex;
LEVANT;
ILLUMENATE;
Clinical Trials;
Peripheral Arterial Disease;
PAD;
Healthcare Startups;
Covidien;
Health Care and Treatment;
Health Testing and Trials;
Business Startups;
Commercialization;
Strategy;
Health Industry;
Medical Devices and Supplies Industry;
United States;
Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (B): Epilogue." Harvard Business School Supplement 315-087, March 2015. (Revised February 2022.)
- 01 May 2020
- News
How Everlywell Pulled Off Its COVID-19 Pivot in Two Weeks
- 23 Aug 2020
- News
In the UK, She Leads the Search for a COVID Vaccine
Kate Bingham (MBA 1991) Kate Bingham (MBA 1991) When she was asked to chair the UK’s Vaccine Taskforce back in May, Kate Bingham (MBA 1991) paused. Despite nearly three decades of experience as a life sciences investor with SV Health Investors, the enormity of leading...
View Details
- Profile
Lindsay Hyde
in a simulated climb of Mt. Everest,” she says. “It was a great way to start the year, to begin thinking about how we want to develop as leaders.” In FIELD 2, Lindsay and her team helped an Indian retailer, Nalli Silk Sarees, develop a new service for the home-goods...
View Details
- 25 Apr 2014
- News
To create breakthrough strategies, harness creativity to the scientific method
rigorous analysis tests them." Rivkin and collaborators A. G. Lafley, Roger Martin, and Nicolaj Siggelkow, recommend combining creativity with the scientific method in an approach where a team representing diverse specialties,...
View Details